Investigator-Initiated Trials (IIT) in China
Your Bridge to CGT Clinical Trials in China
We connect global cell & gene therapy innovators
with top Chinese clinical institutions for fast, structured IIT.
What We Enable
Project Identification
We assess early-stage CGT assets for suitability within the China IIT framework.
Institutional Matching
We introduce selected projects to qualified academic hospitals with proven CGT experience.
Collaboration Structuring
We support both parties in defining roles, regulatory pathways, and data governance before formal engagement.
Optional Operational Coordination
If requested, we can introduce experienced local partners for regulatory, monitoring, or project management services.
Why China for CGT IIT?
China has become a dynamic environment for early CGT validation
Hospital-based IIT pathways that allow early clinical exploration.
Leading academic centers with strong CAR-T and gene editing expertise.
Rapid patient enrollment potential in hematologic and solid tumors.
Increasing regulatory clarity under the evolving NMPA framework.
Explore a China IIT Pathway
If you are evaluating China as a potential early clinical environment for your CGT program, we welcome a structured discussion.
Contact us to assess feasibility and explore institutional alignment.